» Articles » PMID: 31461916

Network Analysis of a Membrane-Enriched Brain Proteome Across Stages of Alzheimer's Disease

Overview
Journal Proteomes
Date 2019 Aug 30
PMID 31461916
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Previous systems-based proteomic approaches have characterized alterations in protein co-expression networks of unfractionated asymptomatic (AsymAD) and symptomatic Alzheimer's disease (AD) brains. However, it remains unclear how sample fractionation and sub-proteomic analysis influences the organization of these protein networks and their relationship to clinicopathological traits of disease. In this proof-of-concept study, we performed a systems-based sub-proteomic analysis of membrane-enriched post-mortem brain samples from pathology-free control, AsymAD, and AD brains ( = 6 per group). Label-free mass spectrometry based on peptide ion intensity was used to quantify the 18 membrane-enriched fractions. Differential expression and weighted protein co-expression network analysis (WPCNA) were then used to identify and characterize modules of co-expressed proteins most significantly altered between the groups. We identified a total of 27 modules of co-expressed membrane-associated proteins. In contrast to the unfractionated proteome, these networks did not map strongly to cell-type specific markers. Instead, these modules were principally organized by their associations with a wide variety of membrane-bound compartments and organelles. Of these, the mitochondrion was associated with the greatest number of modules, followed by modules linked to the cell surface compartment. In addition, we resolved networks with strong associations to the endoplasmic reticulum, Golgi apparatus, and other membrane-bound organelles. A total of 14 of the 27 modules demonstrated significant correlations with clinical and pathological AD phenotypes. These results revealed that the proteins within individual compartments feature a heterogeneous array of AD-associated expression patterns, particularly during the preclinical stages of disease. In conclusion, this systems-based analysis of the membrane-associated AsymAD brain proteome yielded a unique network organization highly linked to cellular compartmentalization. Further study of this membrane-associated proteome may reveal novel insight into the complex pathways governing the earliest stages of disease.

Citing Articles

Multi Layered Omics Approaches Reveal Glia Specific Alterations in Alzheimer's Disease: A Systematic Review and Future Prospects.

Is O, Min Y, Wang X, Oatman S, Abraham Daniel A, Ertekin-Taner N Glia. 2024; 73(3):539-573.

PMID: 39652363 PMC: 11784841. DOI: 10.1002/glia.24652.


Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease.

Shantaraman A, Dammer E, Ugochukwu O, Duong D, Yin L, Carter E Mol Neurodegener. 2024; 19(1):60.

PMID: 39107789 PMC: 11302177. DOI: 10.1186/s13024-024-00749-1.


Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer's pathology.

Kumar P, Goettemoeller A, Espinosa-Garcia C, Tobin B, Tfaily A, Nelson R Nat Commun. 2024; 15(1):2823.

PMID: 38561349 PMC: 10985119. DOI: 10.1038/s41467-024-47028-7.


Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer's Disease.

Shantaraman A, Dammer E, Ugochukwu O, Duong D, Yin L, Carter E bioRxiv. 2024; .

PMID: 38328211 PMC: 10849701. DOI: 10.1101/2024.01.23.576728.


Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes.

Abiose O, Rutledge J, Moran-Losada P, Belloy M, Wilson E, He Z Alzheimers Dement. 2023; 20(3):1851-1867.

PMID: 38146099 PMC: 10984434. DOI: 10.1002/alz.13576.


References
1.
Zambon A, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo C . GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics. 2012; 28(16):2209-10. PMC: 3413395. DOI: 10.1093/bioinformatics/bts366. View

2.
Elias J, Gygi S . Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4(3):207-14. DOI: 10.1038/nmeth1019. View

3.
Sharma K, Schmitt S, Bergner C, Tyanova S, Kannaiyan N, Manrique-Hoyos N . Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci. 2015; 18(12):1819-31. PMC: 7116867. DOI: 10.1038/nn.4160. View

4.
Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

5.
Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View